Optimization Of Hiv Specific Immune Responses In Vivo

体内 HIV 特异性免疫反应的优化

• 批准号: 6684235
• 负责人: ROBERT A SEDER
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6684235
• 关键词: AIDS vaccines; Primates; Rodentias; T lymphocyte; cellular immunity; enzyme linked immunosorbent assay; human immunodeficiency virus 1; immunization; immunoregulation; leukocyte activation /transformation; tissue /cell culture; vaccine development; vector vaccine

Successful development of a vaccine against HIV will likely require the induction of both antibody and/or cellular immune responses sufficient to prevent infection or disease respectively following infectious challenge. While the induction of antibody responses for a variety of other infectious pathogens is readily achieved by a variety of vaccine formulations, live attenuated, recombinant viral vaccines or plasmid DNA vaccines only induce the induction of long-lived cellular immune responses, particularly CD8+ T cell responses. Moreover, since live attenuated HIV vaccines might be precluded from use due to safety concerns and DNA vaccines at present only induce modest CD8+ T cell responses in humans, there is an urgent need to develop ways to enhance the generation and maintenance of CD8+ T cell responses in humans in following immunization. This study focuses on how to optimize the magnitude and duration of CD8+ T cell responses following vaccination in rodents and primates using a variety of vaccine formulations.

成功开发针对HIV的疫苗可能需要诱导抗体和/或细胞免疫反应，足以防止感染挑战后分别预防感染或疾病。尽管多种疫苗制剂可以轻松地诱导各种其他感染性病原体的抗体反应，但仅诱导长期寿命的细胞免疫反应，尤其是CD8+ T细胞反应。此外，由于由于安全问题和DNA疫苗目前仅诱导人类中的适度CD8+ T细胞反应，因此可能无法使用活死的HIV疫苗，因此迫切需要开发方法来增强人类免疫后人类中CD8+ T细胞反应的产生和维持。这项研究的重点是如何使用多种疫苗配方在啮齿动物和灵长类动物接种后优化CD8+ T细胞反应的幅度和持续时间。